Amylyx Pharmaceuticals (AMLX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.39
- Estimate
- -$0.36
- Surprise
- -9.0%
- Score today
- 4.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Amylyx Pharmaceuticals (AMLX) reported a wider loss than forecast — adjusted EPS of -$0.39 against the -$0.36 estimate (a 9.0% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates AMLX Sell at 4.9/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -9.0% surprise compares with a +2.1% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: avexitide
- Concentration risk — Supplier: third-party CMOs
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $30.14
- Price target
- $36.86
- Stop
- $28.94
- Upside to target
- +22.3%
- Reward-to-risk
- 2.1:1
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
AMLX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $3.91B
- P/E (fwd)
- -26.5
- 52-week range
- $10.83–$41.14
- Off 52-week high
- 26.7%
- RSI (14)
- 34
- Volume vs avg
- 0.87×
- Score today
- 4.9/10